Clinuvel Pharmaceuticals Limited (CLVLF)
USD 6.95
(-4.79%)
USD 6.95
(-4.79%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 | 231.12 Million AUD | 19.31% |
| 2023 | 193.71 Million AUD | 34.57% |
| 2022 | 143.94 Million AUD | 32.59% |
| 2021 | 108.56 Million AUD | 33.14% |
| 2020 | 81.54 Million AUD | 30.79% |
| 2019 | 62.34 Million AUD | 45.31% |
| 2018 | 42.9 Million AUD | 49.98% |
| 2017 | 28.6 Million AUD | 42.05% |
| 2016 | 20.13 Million AUD | 47.6% |
| 2015 | 13.64 Million AUD | -20.46% |
| 2014 | 17.15 Million AUD | 8.47% |
| 2013 | 15.81 Million AUD | -1.13% |
| 2012 | 15.99 Million AUD | -20.68% |
| 2011 | 20.16 Million AUD | -31.66% |
| 2010 | 29.5 Million AUD | -29.09% |
| 2009 | 41.61 Million AUD | -24.3% |
| 2008 | 54.97 Million AUD | -18.95% |
| 2007 | 67.82 Million AUD | 297.31% |
| 2006 | 17.07 Million AUD | 69.76% |
| 2005 | 10.05 Million AUD | -1.87% |
| 2004 | 10.24 Million AUD | 27.04% |
| 2003 | 8.06 Million AUD | -23.33% |
| 2002 | 10.52 Million AUD | -23.59% |
| 2001 | 13.76 Million AUD | -10.83% |
| 2000 | 15.44 Million AUD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 211.68 Million AUD | 9.28% |
| 2024 Q2 | 211.68 Million AUD | 0.0% |
| 2024 Q4 | 231.12 Million AUD | 0.0% |
| 2024 FY | 231.12 Million AUD | 19.31% |
| 2023 Q2 | 160.29 Million AUD | 0.0% |
| 2023 Q3 | 193.71 Million AUD | 20.85% |
| 2023 Q1 | 160.29 Million AUD | 11.35% |
| 2023 Q4 | 193.71 Million AUD | 0.0% |
| 2023 FY | 193.71 Million AUD | 34.57% |
| 2022 Q2 | 115.65 Million AUD | 0.0% |
| 2022 Q4 | 143.94 Million AUD | 0.0% |
| 2022 Q1 | 115.65 Million AUD | 6.53% |
| 2022 Q3 | 143.94 Million AUD | 24.47% |
| 2022 FY | 143.94 Million AUD | 32.59% |
| 2021 FY | 108.56 Million AUD | 33.14% |
| 2021 Q4 | 108.56 Million AUD | 0.0% |
| 2021 Q1 | 87.88 Million AUD | 7.77% |
| 2021 Q3 | 108.56 Million AUD | 23.54% |
| 2021 Q2 | 87.88 Million AUD | 0.0% |
| 2020 Q3 | 81.54 Million AUD | 31.36% |
| 2020 Q2 | 62.07 Million AUD | 0.0% |
| 2020 FY | 81.54 Million AUD | 30.79% |
| 2020 Q1 | 62.07 Million AUD | -0.43% |
| 2020 Q4 | 81.54 Million AUD | 0.0% |
| 2019 Q4 | 62.34 Million AUD | 0.0% |
| 2019 Q1 | 45.7 Million AUD | 6.54% |
| 2019 Q2 | 45.7 Million AUD | 0.0% |
| 2019 Q3 | 62.34 Million AUD | 36.4% |
| 2019 FY | 62.34 Million AUD | 45.31% |
| 2018 Q3 | 42.9 Million AUD | 42.27% |
| 2018 Q4 | 42.9 Million AUD | 0.0% |
| 2018 Q1 | 30.15 Million AUD | 5.42% |
| 2018 FY | 42.9 Million AUD | 49.98% |
| 2018 Q2 | 30.15 Million AUD | 0.0% |
| 2017 Q4 | 28.6 Million AUD | 0.0% |
| 2017 FY | 28.6 Million AUD | 42.05% |
| 2017 Q3 | 28.6 Million AUD | 25.25% |
| 2017 Q2 | 22.84 Million AUD | 0.0% |
| 2017 Q1 | 22.84 Million AUD | 13.42% |
| 2016 FY | 20.13 Million AUD | 47.6% |
| 2016 Q4 | 20.13 Million AUD | 0.0% |
| 2016 Q3 | 20.13 Million AUD | 78.52% |
| 2016 Q2 | 11.28 Million AUD | 0.0% |
| 2016 Q1 | 11.28 Million AUD | -17.32% |
| 2015 Q2 | 14.59 Million AUD | 0.0% |
| 2015 FY | 13.64 Million AUD | -20.46% |
| 2015 Q1 | 14.59 Million AUD | -14.9% |
| 2015 Q4 | 13.64 Million AUD | 0.0% |
| 2015 Q3 | 13.64 Million AUD | -6.53% |
| 2014 FY | 17.15 Million AUD | 8.47% |
| 2014 Q2 | 12.71 Million AUD | 0.0% |
| 2014 Q1 | 12.71 Million AUD | -19.59% |
| 2014 Q3 | 17.15 Million AUD | 34.89% |
| 2014 Q4 | 17.15 Million AUD | 0.0% |
| 2013 Q4 | 15.81 Million AUD | 0.0% |
| 2013 Q3 | 15.81 Million AUD | 0.0% |
| 2013 FY | 15.81 Million AUD | -1.13% |
| 2012 Q4 | 15.99 Million AUD | 0.0% |
| 2012 FY | 15.99 Million AUD | -20.68% |
| 2011 Q4 | 20.16 Million AUD | 0.0% |
| 2011 FY | 20.16 Million AUD | -31.66% |
| 2010 FY | 29.5 Million AUD | -29.09% |
| 2010 Q4 | 29.5 Million AUD | 0.0% |
| 2009 Q4 | 41.61 Million AUD | 0.0% |
| 2009 FY | 41.61 Million AUD | -24.3% |
| 2008 FY | 54.97 Million AUD | -18.95% |
| 2008 Q4 | 54.97 Million AUD | 0.0% |
| 2007 Q4 | 67.82 Million AUD | 0.0% |
| 2007 FY | 67.82 Million AUD | 297.31% |
| 2006 FY | 17.07 Million AUD | 69.76% |
| 2006 Q4 | 17.07 Million AUD | 0.0% |
| 2005 Q4 | 10.05 Million AUD | 0.0% |
| 2005 FY | 10.05 Million AUD | -1.87% |
| 2004 FY | 10.24 Million AUD | 27.04% |
| 2004 Q4 | 10.24 Million AUD | 0.0% |
| 2003 Q4 | 8.06 Million AUD | 0.0% |
| 2003 FY | 8.06 Million AUD | -23.33% |
| 2002 Q4 | 10.52 Million AUD | 0.0% |
| 2002 FY | 10.52 Million AUD | -23.59% |
| 2001 FY | 13.76 Million AUD | -10.83% |
| 2000 FY | 15.44 Million AUD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Bioxytran, Inc. | 137.63 Thousand USD | -167821.322% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -494.959% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -302599.988% |
| SQZ Biotechnologies Company | 107.18 Million USD | -115.626% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -16039.552% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -2089.914% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -77.5% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -319285.82% |
| Marizyme, Inc. | 22.01 Million USD | -949.842% |
| Genus plc | 1.02 Billion USD | 77.537% |
| Pharming Group N.V. | 462.85 Million USD | 50.066% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -6876.236% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -46213.725% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -36761.81% |
| ContraFect Corporation | 20.67 Million USD | -1017.673% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -60375.525% |
| IMV Inc. | 31.33 Million USD | -637.618% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -5474.586% |
| ONE Bio Corp. | 70.08 Million USD | -229.774% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -79.849% |
| Mesoblast Limited | 667.9 Million USD | 65.396% |
| MultiCell Technologies, Inc. | 126.22 USD | -183111569.308% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -556.993% |
| Genscript Biotech Corporation | 3.38 Billion USD | 93.175% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -29890.962% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -88359.202% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -3101.263% |
| Biomind Labs Inc. | 73.81 Thousand USD | -312994.934% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -15852.284% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -670.028% |
| Skye Bioscience, Inc. | 11.94 Million USD | -1835.641% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -16914.984% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -8315.709% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -59106.885% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -11702.923% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -33518.655% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -24495.749% |
| EV Biologics, Inc. | 431.71 Thousand USD | -53436.265% |
| Q BioMed Inc. | 3.51 Million USD | -6474.383% |
| GB Sciences, Inc. | 103.44 Thousand USD | -223332.986% |
| Alpha Cognition Inc. | 2.45 Million USD | -9325.266% |
| CSL Limited | 38.02 Billion USD | 99.392% |
| Agentix Corp. | 261.39 Thousand USD | -88320.284% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 48.214% |
| Enzolytics Inc. | 361.7 Million USD | 36.102% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 8.11 Million USD | -2748.103% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -12207.685% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -8778.454% |
| argenx SE | 4.54 Billion USD | 94.912% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -727.095% |
| HST Global, Inc. | 1526.00 USD | -15145610.944% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -384.515% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -23293.853% |
| Halberd Corporation | 10.13 Thousand USD | -2281249.808% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -36032.476% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -2482.63% |
| Zenith Capital Corp. | 7410.00 USD | -3118976.235% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1014445.231% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -71720.771% |
| AVAX Technologies, Inc. | 7.37 Million USD | -3032.962% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -88329.757% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -24806.602% |
| Ember Therapeutics, Inc. | 184.00 USD | -125610524.457% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 62.24 Thousand USD | -371194.739% |
| Helix BioMedix, Inc. | 3.02 Million USD | -7540.231% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -338.556% |
| Kadimastem Ltd | 2.3 Million USD | -9931.056% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 14.56 Million USD | -1487.355% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -404712.325% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -10005248.442% |
| LadRx Corporation | 2.3 Million USD | -9914.531% |
| Cell Source, Inc. | 195.17 Thousand USD | -118321.051% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -47994.929% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -65259.852% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -65259.852% |
| Affymax, Inc. | 7.44 Million USD | -3005.247% |
| Mobile Lads Corp. | 52.00 USD | -444468263.462% |
| Itoco Inc. | 1.4 Million USD | -16407.976% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -241516.974% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -217941.084% |
| International Stem Cell Corporation | 5.39 Million USD | -4188.006% |
| CytoDyn Inc. | 11.13 Million USD | -1975.463% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -161556.512% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1292537.299% |
| Qrons Inc. | 420.00 USD | -55029316.429% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -59858.739% |
| SYBLEU INC | 330.46 Thousand USD | -69838.254% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -41761.108% |
| Rebus Holdings, Inc. | 5000.00 USD | -4622370.98% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -56351.18% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -1440.636% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -1294.074% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -292461.454% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -26629.466% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -2974.678% |
| Neutra Corp. | 2851.00 USD | -8106653.736% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -613.212% |
| PureTech Health plc | 693.97 Million USD | 66.696% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -2763.598% |
| IXICO plc | 15.84 Million USD | -1358.754% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -2690.673% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -123.688% |
| CSL Limited | 38.02 Billion USD | 99.392% |
| Cellectis S.A. | 333.99 Million USD | 30.8% |